Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Oramed Pharmaceuticals Inc. (ORMP) had Normalized Income after Taxes of $78.16M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$78.16M |
|
-- |
|
-- |
|
$2.77M |
|
$-2.77M |
|
$104.35M |
|
$101.59M |
|
$101.59M |
|
$78.16M |
|
$78.16M |
|
$78.16M |
|
|
Normalized Income after Taxes |
$78.16M |
$-2.77M |
|
$-2.73M |
|
41.04M |
|
42.50M |
|
$1.90 |
|
$1.84 |
|
| Balance Sheet Financials | |
$53.41M |
|
$0.53M |
|
$316.24M |
|
$369.64M |
|
$10.73M |
|
-- |
|
$41.44M |
|
$52.17M |
|
$317.47M |
|
$317.47M |
|
$317.47M |
|
41.31M |
|
| Cash Flow Statement Financials | |
$-3.12M |
|
$-15.18M |
|
$-12.31M |
|
$45.95M |
|
$15.24M |
|
$-30.70M |
|
$3.13M |
|
$-10.44M |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.98 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.12M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
24.62% |
|
24.62% |
|
21.14% |
|
24.62% |
|
$7.68 |
|
$-0.07 |
|
$-0.07 |
|